Phase II study confirms efficacy of Bavarian Nordic's Covid-19 vaccine
A study of 103 people who had previously received the vaccine found that it offers protection against all variants of the coronavirus – however, the trial took place before the Omicron variant was discovered.
by mikkel aabenhus hemmingsen, translated by catherine brett
On Sunday, Bavarian Nordic publicized results from its phase II study of its corona vaccine, ABMCoV, which it has inlicensed from biotech company Adaptvac.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic: We can adapt our vaccine if necessary
For subscribers
EMA begins rolling review of another Covid-19 vaccine
For subscribers
